The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

They say that change takes time. Well, that's not the case for RNA. The small biological molecule acts like a switchboard ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

New research suggests that the formation of stress granules, clumps of proteins and RNA under stress, is a potential root ...

UMD researchers have discovered key mechanisms in gene regulation that could improve the design of RNA-based medicines.

There are many molecules with therapeutic potential, but it can be a challenge to deliver them to the right places at the ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

New research challenges previous assumptions about RNA transport, finding that RNA can carry instructions across generations.